Delta Lloyd NV boosted its stake in shares of Zimmer Biomet Holdings Inc. (NYSE:ZBH) by 25.2% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 14,642 shares of the company’s stock after buying an additional 2,947 shares during the period. Delta Lloyd NV’s holdings in Zimmer Biomet Holdings were worth $1,904,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in ZBH. Cohen & Steers Inc. increased its stake in shares of Zimmer Biomet Holdings by 2,057.7% in the second quarter. Cohen & Steers Inc. now owns 2,814,345 shares of the company’s stock valued at $60,874,000 after buying an additional 2,683,915 shares in the last quarter. Winslow Capital Management LLC acquired a new stake in shares of Zimmer Biomet Holdings during the second quarter valued at about $310,013,000. Ameriprise Financial Inc. increased its stake in shares of Zimmer Biomet Holdings by 38.9% in the second quarter. Ameriprise Financial Inc. now owns 4,853,226 shares of the company’s stock valued at $584,179,000 after buying an additional 1,359,249 shares in the last quarter. Massachusetts Financial Services Co. MA increased its stake in shares of Zimmer Biomet Holdings by 8.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 17,028,139 shares of the company’s stock valued at $2,049,848,000 after buying an additional 1,340,461 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Zimmer Biomet Holdings by 12.3% in the second quarter. Vanguard Group Inc. now owns 11,940,582 shares of the company’s stock valued at $1,437,408,000 after buying an additional 1,306,447 shares in the last quarter. 85.05% of the stock is owned by institutional investors and hedge funds.

Institutional Ownership by Quarter for Zimmer Biomet Holdings (NYSE:ZBH)

Zimmer Biomet Holdings Inc. (NYSE:ZBH) traded up 1.39% during midday trading on Tuesday, hitting $103.40. The stock had a trading volume of 2,183,053 shares. The stock has a market cap of $20.71 billion, a price-to-earnings ratio of 57.89 and a beta of 1.28. The company has a 50-day moving average of $112.33 and a 200-day moving average of $121.63. Zimmer Biomet Holdings Inc. has a 1-year low of $88.27 and a 1-year high of $133.21.

Zimmer Biomet Holdings (NYSE:ZBH) last issued its quarterly earnings results on Monday, October 31st. The company reported $1.79 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $1.79. The business had revenue of $1.83 billion for the quarter, compared to the consensus estimate of $950.20 million. Zimmer Biomet Holdings had a return on equity of 16.48% and a net margin of 3.46%. The firm’s quarterly revenue was up 4.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.64 earnings per share. Equities research analysts forecast that Zimmer Biomet Holdings Inc. will post $7.92 EPS for the current year.

TRADEMARK VIOLATION WARNING: “Delta Lloyd NV Increases Position in Zimmer Biomet Holdings Inc. (ZBH)” was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another domain, it was copied illegally and republished in violation of U.S. and international copyright law. The original version of this news story can be read at https://www.thecerbatgem.com/2016/11/29/delta-lloyd-nv-increases-position-in-zimmer-biomet-holdings-inc-zbh.html.

ZBH has been the subject of several research analyst reports. SunTrust Banks Inc. initiated coverage on Zimmer Biomet Holdings in a research note on Thursday, August 11th. They issued a “buy” rating and a $155.00 price objective for the company. Jefferies Group reaffirmed a “buy” rating and set a $150.00 price target on shares of Zimmer Biomet Holdings in a research note on Monday, August 8th. Canaccord Genuity reaffirmed a “buy” rating and set a $130.00 price target (down from $150.00) on shares of Zimmer Biomet Holdings in a research note on Monday, October 31st. Argus reaffirmed a “buy” rating and set a $140.00 price target on shares of Zimmer Biomet Holdings in a research note on Thursday, September 22nd. Finally, RBC Capital Markets set a $143.00 price target on Zimmer Biomet Holdings and gave the stock a “buy” rating in a research note on Wednesday, September 14th. Four equities research analysts have rated the stock with a hold rating, twenty have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $131.15.

In related news, insider Daniel E. Williamson sold 2,716 shares of the stock in a transaction that occurred on Thursday, September 8th. The stock was sold at an average price of $129.96, for a total transaction of $352,971.36. Following the sale, the insider now owns 2,000 shares of the company’s stock, valued at $259,920. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 1.22% of the company’s stock.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc, formerly Zimmer Holdings, Inc, is engaged designing, manufacturing and marketing orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; spine, bone healing, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

5 Day Chart for NYSE:ZBH

Receive News & Stock Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related stocks with our FREE daily email newsletter.